This application proposes to continue, extend and add new angles to the investigation of the role of angiotensin II (Ang II) in myocyte remodeling and signaling mechanisms for it. It is based on new findings of cross-talk between epidermal receptor and the Ang II type 1 (AT1) receptor in extracellular signal-response kinase (ERK), as well as involvement of several non-receptor tyrosine kinases and tyrosine phosphatases which include Janus kinase (JAK2), proline rich tyrosine kinase (PYK2), SH2 containing phosphatase-2 and - 1 (SHP-2 and SHP-1) protein kinases C (particularly PKC-delta). They form a large complex with other caffold proteins Gab1, and small G-protein Rap1, and they are responsible for activation of cJun NH2- kinase (JNK), cellular migration and make these cells responsive to favorable action of statins. We propose to add a new angle to studies on signaling mechanism regulating prolonged expressionof AT1 byAT2. Based on our preliminary finding that cardiac hypertrophy is preceded by pressure overload, which induces a marked increase in the angiotensin II type 2 receptor (AT2) expression before long term increase in the type 1 receptor (AT1) expression, we will evaluate the hypothesis that pressure overload induced cardiac hypertrophy and AT1 expression is controlled by AT2, which activate the transcription factor promyelocytic zinc finger protein PLZF. These studies will provide important insights into the mechanism of cardiovascular remodeling and will be useful for developing specific therapeutic remedies and preventative approaches to cope with morbid and mortal diseases due to cardiovascular remodeling.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37HL058205-11
Application #
7214756
Study Section
Special Emphasis Panel (NSS)
Program Officer
Barouch, Winifred
Project Start
1997-04-10
Project End
2011-03-31
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
11
Fiscal Year
2007
Total Cost
$372,015
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Biochemistry
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Faghih, Mahya; Hosseini, Sayed M; Smith, Barbara et al. (2015) Knockout of Angiotensin AT2 receptors accelerates healing but impairs quality. Aging (Albany NY) 7:1185-97
Huang, Jianbin; Yamashiro, Yoshito; Papke, Christina L et al. (2013) Angiotensin-converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4-deficient mice. Sci Transl Med 5:183ra58, 1-11
Hafko, Roman; Villapol, Sonia; Nostramo, Regina et al. (2013) Commercially available angiotensin II At? receptor antibodies are nonspecific. PLoS One 8:e69234
Wang, Ning; Frank, Gerald D; Ding, Ronghua et al. (2012) Promyelocytic leukemia zinc finger protein activates GATA4 transcription and mediates cardiac hypertrophic signaling from angiotensin II receptor 2. PLoS One 7:e35632
Biswas, Kazal Boron; Nabi, Ahm Nurun; Arai, Yoshie et al. (2011) Qualitative and quantitative analyses of (pro)renin receptor in the medium of cultured human umbilical vein endothelial cells. Hypertens Res 34:735-9
Inagami, Tadashi (2011) Mitochondrial angiotensin receptors and aging. Circ Res 109:1323-4
Sun, Xiao; Iida, Shinichiro; Yoshikawa, Ayumu et al. (2011) Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely. Hypertens Res 34:701-6
Verlander, Jill W; Hong, Seongun; Pech, Vladimir et al. (2011) Angiotensin II acts through the angiotensin 1a receptor to upregulate pendrin. Am J Physiol Renal Physiol 301:F1314-25
Sakoda, Mariyo; Ichihara, Atsuhiro; Kurauchi-Mito, Asako et al. (2010) Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes. Am J Hypertens 23:575-80
Biswas, Kazal Boron; Nabi, A H M Nurun; Arai, Yoshie et al. (2010) Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro. Hypertens Res 33:1053-9

Showing the most recent 10 out of 78 publications